Beneficial effects of a nano formulation of pomegranate seed oil, GranaGard, on the cognitive function of multiple sclerosis patients

  • Panayiota Petrou
    Multiple sclerosis Center and cell therapies Unit, Unit and Laboratory of Neuroimmunology and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Jerusalem
    Search for articles by this author
  • Ariel Ginzberg
    Multiple sclerosis Center and cell therapies Unit, Unit and Laboratory of Neuroimmunology and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Jerusalem
    Search for articles by this author
  • Orli Binyamin
    Multiple sclerosis Center and cell therapies Unit, Unit and Laboratory of Neuroimmunology and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Jerusalem
    Search for articles by this author
  • Dimitrios Karussis
    Corresponding author.
    Multiple sclerosis Center and cell therapies Unit, Unit and Laboratory of Neuroimmunology and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Jerusalem
    Search for articles by this author


      • No adverse events were recorded during a 3-month treatment of patients with MS with GranaGard, a brain targeting nano-formulation of PSO.
      • GranaGard administration seems to induce short-term beneficial effects and to improve/stabilize cognitive disability in MS patients.
      • Putative mechanisms of action of GranaGard are mostly related to its strong anti-oxidative effects.



      Though often neglected, cognitive impairment is a common feature of multiple sclerosis in 43–70% of patients. None of the novel MS treatment seems to substantially affect or restore cognitive disability in MS. GranaGard (Granalix Bio Technologies LTD) is a food supplement shown to prevent neuronal death in several animal models of neurological diseases. Capsules of GranaGard comprise a self-emulsion nano formulation of pomegranate seed oil (PSO). This oil contains 80–90% of Punicic Acid (PA), one of the strongest natural antioxidants. In animal experiments, administration of GranaGard results in conjugation with linoleic acid (CLA), the main metabolite of PA, which is a well-known neuroprotective agent.


      To investigate whether GranaGard administration has an effect on the cognitive state of MS patients.


      This is a single center, randomized double blind clinical trial that started in May 2018. The study included 30 MS patients; half of them (Group-A) were given GranaGard for the first three months and then placebo pills containing soybean oil for additional three months. Patients in Group-B received placebo for the first three months, and GranaGard for the following three months. GranaGard was administrated in addition to their immunomodulatory MS-treatments. Subsequently, all patients received GranaGard for additional six months. Patients were required to visit the neurologist at baseline (inclusion, visit 1) and at 3 months after treatment-initiation at each cycle of the trial (visits 2 and 3). During the follow up visits, clinical and cognitive examinations were performed, including Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC: 25 ft walking test, 9 PEG hole test & PASAT). Cognitive tests included The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery: 1) Symbol Digit Modalities Test (SDMT); 2) California Verbal Learning Test – Second Edition (CVLT-II); 3) and Brief Visuospatial Memory Test – Revised (BVMT-R). Cognitive outcomes were normalized to the healthy population and expressed as z-scores, depended on age, gender and education. Short quality of life and fatigue questionnaires (SF-12, MFIS-5) were also provided by the participants.


      No serious adverse effects, related to the product, were observed during the study period. All patients receiving GranaGard reported a ‘’positive‘’ effect in their ADL while using the product. While there were no significant differences in the clinical parameters of disability (EDSS scores) between the treatment groups, there was a trend of beneficial effect of GranaGard, on the verbal testing during the first 3-month period of treatment. The z score for CVLT-II, significantly increased (from 0.891 to 1.415, p = 0.012, Wilcoxon rank test) at 3-months in the group of patients who were treated with GranaGard, as compared to baseline. A similar (but not statistically significant) trend was seen also in the BVMTr testing during the same 3 months-period, whereas there was no change in the SDMT. The overall average z-score of all three cognitive functions was significantly improved in the three months of Granagard treatment (-0.0077 at 3 months vs 0.462 at baseline, p = 0.034, Wilcoxon rank test). During the same 3-months period there were no significant changes in the placebo-treated group. For the patients receiving GranaGard in the initial 3 months, the value of z score of CVLT-II remained high (z = 1.415) also at the following three months (while they received placebo), suggesting a longer lasting effect for at least 3 months after discontinuation of the drug.


      This is the first study in which GranaGard, a brain targeted nano-formulation of PSO, was tested in humans. Our results in this small pilot, controlled trial provide indications that GranaGard administration to MS patients might improve/stabilize cognitive disability. Larger studies with longer duration, are needed to confirm these initial observations.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Reich D.S.
        • Lucchinetti C.F.
        • Calabresi P.A.
        Multiple sclerosis.
        N. Engl. J. Med. 2018; 378: 169-180
        • Kappos L.
        • et al.
        Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
        Mult. Scler. 2016; 22: 1297-1305
        • Chiaravalloti N.D.
        • DeLuca J.
        Cognitive impairment in multiple sclerosis.
        Lancet Neurol. 2008; 7: 1139-1151
        • Benedict R.H.B.
        • et al.
        Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.
        Lancet Neurol. 2020; 19: 860-871
        • De Giglio L.
        • et al.
        Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
        Neurology. 2019; 93: e733-e746
        • Geisler M.W.
        • et al.
        The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.
        Arch. Neurol. 1996; 53: 185-188
        • Krupp L.B.
        • et al.
        Donepezil improved memory in multiple sclerosis in a randomized clinical trial.
        Neurology. 2004; 63: 1579-1585
        • Krupp L.B.
        • et al.
        Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis.
        Neurology. 2011; 76: 1500-1507
        • Landmeyer N.C.
        • et al.
        Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: a meta-analysis.
        Neurology. 94. 2020: e2373-e2383
        • Lovera J.
        • et al.
        Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial.
        Mult. Scler. 2007; 13: 376-385
        • Sano M.
        • et al.
        A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
        N. Engl. J. Med. 1997; 336: 1216-1222
        • Satchidanand N.
        • et al.
        Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
        Mult. Scler. 2020; 26: 91-98
        • Shaygannejad V.
        • et al.
        Effects of rivastigmine on memory and cognition in multiple sclerosis.
        Can. J. Neurol. Sci. 2008; 35: 476-481
        • Lovell M.A.
        • Markesbery W.R.
        Oxidative damage in mild cognitive impairment and early Alzheimer's disease.
        J. Neurosci. Res. 2007; 85: 3036-3040
        • Pohl F.
        • Kong Thoo Lin P.
        The potential use of plant natural products and plant extracts with antioxidant properties for the prevention/treatment of neurodegenerative diseases: in vitro, in vivo and clinical trials.
        Molecules. 2018; 23
        • Gilgun-Sherki Y.
        • Melamed E.
        • Offen D.
        The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy.
        J. Neurol. 2004; 251: 261-268
        • Miller E.
        • Wachowicz B.
        • Majsterek I.
        Advances in antioxidative therapy of multiple sclerosis.
        Curr. Med. Chem. 2013; 20: 4720-4730
        • Miller E.D.
        • et al.
        A review of various antioxidant compounds and their potential utility as complementary therapy in multiple sclerosis.
        Nutrients. 2019; 11
        • Mirshafiey A.
        • Mohsenzadegan M.
        Antioxidant therapy in multiple sclerosis.
        Immunopharmacol. Immunotoxicol. 2009; 31: 13-29
        • Binyamin O.
        • et al.
        Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant.
        Int. J. Nanomedicine. 2015; 10: 7165-7174
        • Thompson A.J.
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Glanz B.I.
        • et al.
        Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis.
        Mult. Scler. 2007; 13: 1004-1010
        • Morrow S.A.
        • et al.
        The effects ofl-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial.
        J. Neurol. 2009; 256: 1095-1102
        • Rao S.M.
        • et al.
        Cognitive Dysfunction in Multiple Sclerosis. I. Frequency, patterns, and Prediction. 41. Neurology, 1991: 685-691
        • Binyamin O.
        • et al.
        Continuous administration of Nano-PSO significantly increased survival of genetic CJD mice..
        Neurobiol Dis. 2017; (10.1016/j.nbd.2017.08.012)
        • Binyamin O.
        • et al.
        Brain targeting of 9c,11t-Conjugated Linoleic Acid, a natural calpain inhibitor, preserves memory and reduces Aβ and P25 accumulation in 5XFAD mice..
        Sci Rep. 2019; (10.1038/s41598-019-54971-9)
        • Brandstadter R.
        • et al.
        Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
        Mult. Scler. 2020; 26: 1752-1764
        • Jakimovski D.
        • et al.
        Cognitive profiles of aging in multiple sclerosis.
        Front. Aging Neurosci. 2019; 11: 105
        • Johnen A.
        • et al.
        Distinct cognitive impairments in different disease courses of multiple sclerosis-A systematic review and meta-analysis.
        Neurosci. Biobehav. Rev. 2017; 83: 568-578
        • Ruano L.
        • et al.
        Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
        Mult. Scler. 2017; 23: 1258-1267
        • LaRocca N.G.
        • et al.
        The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
        Mult. Scler. 2018; 24: 1469-1484
        • Langdon D.W.
        • et al.
        Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).
        Mult. Scler. 2012; 18: 891-898
        • Benedict R.
        • et al.
        Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).
        Journal of the International Neuropsychological Society. 2006; 12: 549-558
        • Benedict R.H.
        • et al.
        Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis.
        Mult. Scler. 2017; 23: 721-733
        • Corfield F.
        • Langdon D.
        A systematic review and meta-analysis of the brief cognitive assessment for multiple sclerosis (BICAMS).
        Neurol Ther. 2018; 7: 287-306
        • Goldman M.D.
        • et al.
        Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
        Neurology. 2019; 93: e1921-e1931
        • Delis D.C.
        • et al.
        Integrating clinical assessment with cognitive neuroscience: construct validation of the California Verbal Learning Test.
        J. Consult. Clin. Psychol. 1988; 56: 123-130
        • Gaines J.J.
        • et al.
        New error type and recall consistency indices for the Brief Visuospatial Memory Test - Revised: performance in healthy adults and multiple sclerosis patients.
        Clin. Neuropsychol. 2008; 22: 851-863
        • Montine T.J.
        • et al.
        Lipid peroxidation in aging brain and Alzheimer's disease.
        Free Radic. Biol. Med. 2002; 33: 620-626
        • Morris M.C.
        The role of nutrition in Alzheimer's disease: epidemiological evidence.
        Eur. J. Neurol. 2009; 16 (Suppl): 1-7
        • Yaffe K.
        • et al.
        Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial.
        Neurology. 2004; 63: 1705-1707
        • Petersen R.C.
        • et al.
        Vitamin E and donepezil for the treatment of mild cognitive impairment.
        N. Engl. J. Med. 2005; 352: 2379-2388
        • Sawant R.R.
        • Torchilin V.P.
        Multifunctionality of lipid-core micelles for drug delivery and tumour targeting.
        Mol. Membr. Biol. 2010; 27: 232-246
        • Spector R.
        Fatty acid transport through the blood-brain barrier.
        J. Neurochem. 1988; 50: 639-643